Lisbon, Portugal, 2017-11-14 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference

Roger R. Beerli, CSO of NBE-Therapeutics, will present an update on the company's ADC development activities

Read more

Basel, Switzerland, 2017-11-02 - NBE-Therapeutics to present update on R&D activities at 2017 HPAPI World Congress

Roger R. Beerli, CSO of NBE-Therapeutics, will present an update on the company's ADC development activities

Read more

Vienna, Austria, 2017-09-22 - NBE-Therapeutics to present update on R&D activities at 2nd Annual Cancer Immunotherapy Summit

Roger R. Beerli, CSO of NBE-Therapeutics, invited to present an update on the company's ADC discovery activities

Read more

Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

Ulf Grawunder, CEO of NBE-Therapeutics, will present an update on NBE-Therapeutics' ADC development activities at the 2nd Annual Antibody Drug Conjugates (ADC) Summit, Barcelona, Spain

Read more

London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.

Ulf Grawunder, CEO of NBE-Therapeutics, invited to present an update on NBE-Therapeutics' ADC development activities at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.

Read more

next >